In vitro selection of CD70 binding aptamer and its application in a biosensor design for sensitive detection of SKOV-3 ovarian cells

Bayat, Payam; Taghdisi, Seyed Mohammad; Rafatpanah, Houshang; Abnous, Khalil; Ramezani, Mohammad

doi:10.1016/j.talanta.2018.10.063

Cited by 22 publications

(11 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Modified aptamers can label or kill tumors that express specific markers. For example, the aptamer of CD70, which is conjugated with ATTO-647N fluorescence, acts as an “aptasensor” for the sensitive and fast detection of CD70-positive SKOV-3 19 . In an immunotherapeutic study, a programmed cell death ligand-1 (PD-L1)-targeting aptamer suppressed tumor growth by increasing the number of tumor-infiltrating T cells 20 …”

Section: Introductionmentioning

confidence: 99%

A DNA Aptamer Targeting Galectin-1 as a Novel Immunotherapeutic Strategy for Lung Cancer

Tsai

Liang

et al. 2019

Molecular Therapy - Nucleic Acids

View full text Add to dashboard Cite

Galectin-1 (Gal-1) is a pleiotropic homodimeric b-galactosidebinding protein with a single carbohydrate recognition domain. It has been implicated in several biological processes that are important during tumor progression. Several lines of evidence have indicated that Gal-1 is involved in cancer immune escape and induces T cell apoptosis. These observations all emphasized Gal-1 as a novel target for cancer immunotherapy. Here, we developed a novel Gal-1-targeting DNA aptamer (AP-74 M-545) and demonstrated its antitumor effect by restoring immune function. AP-74 M-545 binds to Gal-1 with high affinity. AP-74 M-545 targets tumors in murine tumor models but suppresses tumor growth only in immunocompetent C57BL/6 mice, not in immunocompromised nonobese diabetic (NOD)/severe combined immunodeficiency (SCID) mice. Immunohistochemistry revealed increased CD4 + and CD8 + T cells in AP-74 M-545-treated tumor tissues. AP-74 M-545 suppresses T cell apoptosis by blocking the binding of Gal-1 to CD45, the main receptor and apoptosis mediator of Gal-1 on T cells. Collectively, our data suggest that the Gal-1 aptamer suppresses tumor growth by blocking the interaction between Gal-1 and CD45 to rescue T cells from apoptosis and restores T cell-mediated immunity. These results indicate that AP-74 M-545 may be a potential strategy for cancer immunotherapy.

show abstract

Section: Introductionmentioning

confidence: 99%

A DNA Aptamer Targeting Galectin-1 as a Novel Immunotherapeutic Strategy for Lung Cancer

Tsai

Liang

et al. 2019

Molecular Therapy - Nucleic Acids

View full text Add to dashboard Cite

show abstract

“…Its overexpression is related to a series of tumors including ovarian cancer. Bayat et al (2019) screened DNA aptamers with affinity for histidine-labeled recombinant CD70 protein and CD70-overexpressing SKOV3 cells and identified that Apt928 could obstruct the combination of CD70 and CD27. The detection limit in SKOV3 cells was determined by labeling Apt928 with ATTO 674 N. Although the target proteins mentioned here are not recommended ovarian cancer biomarkers, there are different types of ovarian cancers with different proteins expressed during tumorigenesis.…”

Section: Screening For Aptamers Targeting Ovarian Cancermentioning

confidence: 99%

“…Apart from detecting cancer biomarkers, aptamers can also be used in other aspects of cancer diagnosis. Bayat et al (2019) used the newly screened aptamer Apt928 to detect the number of cancer cells; the detection limit of their aptasensor was 14 cells/ml, and the detection range was 10 to 10 5 cells/100 μl. Tsai et al (2017) designed an integrated microfluidic system using the CX-BG1-10-A aptamer for the detection of ovarian cancer-derived BG-1 cells, and the detection steps included RBC lysis, WBC depletion, and circulating tumor cell isolation, which made it more sensitive compared to antibody-based detection systems; this microfluidic system completed the entire process within an hour without human intervention and exhibited a high capture rate and a low false positive rate, thereby saving time.…”

Section: Applications Of Aptamers In Ovarian Cancer Diagnosismentioning

confidence: 99%

Applications of Aptamers in the Diagnosis and Treatment of Ovarian Cancer: Progress From 2016 to 2020

Ruan

2021

Front. Genet.

View full text Add to dashboard Cite

Nucleic acid aptamers are short single-stranded DNA or RNA oligonucleotides selected from a random single-stranded nucleic acid library using systematic evolution of ligands by exponential enrichment technology. To allow them to bind to molecular targets with the same specificity and precision as that of antibodies, aptamers are folded into secondary or tertiary structures. However, compared to antibodies, aptamers are not immunogenic and are easier to synthesize. Furthermore, they are chemically modified, which protects them from degradation by nucleases. Hence, due to their stability and favorable targeting ability, aptamers are promising for the diagnosis and treatment of diseases. Ovarian cancer has the worst prognosis among all gynecological diseases and is usually diagnosed at the medium and advanced stages due to its nonspecific symptoms. Relapse is common, even if patients receive a standard therapeutic regimen including surgery and chemotherapy; simultaneously, drug resistance and adverse effects are reported in a several patients. Therefore, the safer and more efficient diagnostic and treatment method for ovarian cancer is imperative. Scientists have been trying to utilize aptamer technology for the early diagnosis and accurate treatment of ovarian cancer and some progress has been made in this field. This review discusses the screening of nucleic acid aptamers by targeting ovarian cancer cells and the application of aptamers in the diagnosis and treatment of ovarian cancer.

show abstract

“…Zhou et al[56] obtained two kinds of aptamers that recognize DKK1, one is slow-off aptamer, and the experimental results show that it can be used for aptamer-based ELISA assay, while another fast-off aptamer is more suitable for flow cytometry and spot-blot. In addition, the combination of molecular beacons[57], which have stem-ring structures and contain fluorescent and quenching agents, and fluorescent dyes[58] with aptamers targeting tumors has also been proven to be useful for detecting or imaging tumors. This provides more potential methods for in vitro detection of liver cancer.…”

Section: Application Of Aptamers In the Targeted Diagnosis Of Liver Cmentioning

confidence: 99%

Screening of aptamers and their potential application in targeted diagnosis and therapy of liver cancer

Zhang¹,

Zhong²,

Yang³

et al. 2019

WJG

View full text Add to dashboard Cite

Aptamers are a class of single oligonucleotide molecules (DNA or RNA) that are screened from random DNA or RNA oligonucleotide chain libraries by the systemic evolution of ligands by exponential enrichment technology. The selected aptamers are capable of specifically binding to different targeting molecules, which is achieved by the three-dimensional structure of aptamers. Aptamers are similar in function to monoclonal antibodies, and therefore, they are also referred to as "chemical antibodies". Due to their high affinity and specificity and low immunogenicity, aptamers are topics of intense interest in today's biological targeting research especially in tumor research. They not only have high potential for clinical advances in tumor targeting detection but also are highly promising as targeted tumor drug carriers for use in tumor therapy. Various experimental studies have shown that aptamer-based diagnostic and therapeutic methods for liver cancer have great potential for application. This paper summarizes the structure, characteristics, and screening methods of aptamers and reviews the recent research progress on nucleic acid aptamers in the targeted diagnosis and treatment of liver cancer.

show abstract

In vitro selection of CD70 binding aptamer and its application in a biosensor design for sensitive detection of SKOV-3 ovarian cells

Cited by 22 publications

References 32 publications

A DNA Aptamer Targeting Galectin-1 as a Novel Immunotherapeutic Strategy for Lung Cancer

A DNA Aptamer Targeting Galectin-1 as a Novel Immunotherapeutic Strategy for Lung Cancer

Applications of Aptamers in the Diagnosis and Treatment of Ovarian Cancer: Progress From 2016 to 2020

Screening of aptamers and their potential application in targeted diagnosis and therapy of liver cancer

Contact Info

Product

Resources

About